First-line therapy for T cell lymphomas: a retrospective
population-based analysis of 906 T cell lymphoma patients

J 2019

First-line therapy for T cell lymphomas: a retrospective population-based analysis of 906 T cell lymphoma patients

JANÍKOVÁ, Andrea, Renata CHLOUPKOVÁ, Vit CAMPR, Pavel KLENER, Jitka HAMOUZOVA et. al.

Základní údaje

Originální název

First-line therapy for T cell lymphomas: a retrospective population-based analysis of 906 T cell lymphoma patients

Autoři

JANÍKOVÁ, Andrea (203 Česká republika, garant, domácí), Renata CHLOUPKOVÁ (203 Česká republika, domácí), Vit CAMPR (203 Česká republika), Pavel KLENER (203 Česká republika), Jitka HAMOUZOVA (203 Česká republika), David BELADA (203 Česká republika), Vit PROCHAZKA (203 Česká republika), Robert PYTLIK (203 Česká republika), Jan PIRNOS (203 Česká republika), Juraj DURAS (203 Česká republika), Heidi MOCIKOVA (203 Česká republika), Zbyněk BORTLÍČEK (203 Česká republika, domácí), Natasa KOPALOVA (203 Česká republika), Jiří MAYER (203 Česká republika, domácí) a Marek TRNENY (203 Česká republika)

Vydání

Annals of hematology, New York, Springer Verlag, 2019, 0939-5555

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 2.904

Kód RIV

RIV/00216224:14110/19:00112767

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1007/s00277-019-03694-y

UT WoS

000475694100018

Klíčová slova anglicky

T cell lymphoma; Auto-SCT; Etoposide; Prognosis

Štítky

14110212, 14119612, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 11. 5. 2020 13:26, Mgr. Tereza Miškechová

Anotace

V originále

Peripheral T cell lymphomas (PTLs) have a globally poor prognosis. The CHOP regimen shows insufficient efficacy; first-line consolidation with autologous stem cell transplantation (auto-SCT) is a promising strategy but has never been confirmed by randomized data. We analyzed retrospectively 906 patients diagnosed with PTL between 1999 and 2015. Chemotherapy was given to 862 patients, and 412 of them were <60years. In this subset, we compared induction with CHOP (n=113) vs. CHOEP (n=68) and tested auto-SCT (n=79) vs. no SCT (n=73) in the intent-to-treat analysis. The median age of the whole cohort at diagnosis was 60years (range; 18-91); the median follow-up was 4.3years (range; 0.1-17.8). A shorter overall survival (OS) was associated with the male gender, age >= 60years, stage III/IV, performance status >= 2, bulky tumor >= 10cm, and elevated LDH. CHOEP induction showed a better 5-year PFS (25.0% vs. 32.9%; p.001), and 5-year OS (65.6% vs. 47.6%; p.008) than CHOP. Auto-SCT compared to no SCT brought a 5-year OS of 49.2% vs. 59.5% (p.187). Auto-SCT did not influence the OS in low-risk or low-intermediate risk PTLs. The high-intermediate and high-risk IPIs displayed a worse 5-year OS in auto-SCT arm (17.7% vs.46.2%; p.049); however, 73.9% of the patients never received planned auto-SCT. Our population-based analysis showed the superiority of CHOEP over CHOP in first-line treatment. We confirm the 5-year OS of around 50% in PTLs undergoing auto-SCT. However, the intended auto-SCT could not be given in 73.9% of the high-risk PTLs.

Citovat

JANÍKOVÁ, Andrea, Renata CHLOUPKOVÁ, Vit CAMPR, Pavel KLENER, Jitka HAMOUZOVA, David BELADA, Vit PROCHAZKA, Robert PYTLIK, Jan PIRNOS, Juraj DURAS, Heidi MOCIKOVA, Zbyněk BORTLÍČEK, Natasa KOPALOVA, Jiří MAYER a Marek TRNENY. First-line therapy for T cell lymphomas: a retrospective population-based analysis of 906 T cell lymphoma patients. Annals of hematology. New York: Springer Verlag, 2019, roč. 98, č. 8, s. 1961-1972. ISSN 0939-5555. Dostupné z: https://dx.doi.org/10.1007/s00277-019-03694-y.

@article{1611116,
   author = {Janíková, Andrea and Chloupková, Renata and Campr, Vit and Klener, Pavel and Hamouzova, Jitka and Belada, David and Prochazka, Vit and Pytlik, Robert and Pirnos, Jan and Duras, Juraj and Mocikova, Heidi and Bortlíček, Zbyněk and Kopalova, Natasa and Mayer, Jiří and Trneny, Marek},
   article_location = {New York},
   article_number = {8},
   doi = {http://dx.doi.org/10.1007/s00277-019-03694-y},
   keywords = {T cell lymphoma; Auto-SCT; Etoposide; Prognosis},
   language = {eng},
   issn = {0939-5555},
   journal = {Annals of hematology},
   title = {First-line therapy for T cell lymphomas: a retrospective population-based analysis of 906 T cell lymphoma patients},
   url = {http://dx.doi.org/10.1007/s00277-019-03694-y},
   volume = {98},
   year = {2019}
}

TY  - JOUR
ID  - 1611116
AU  - Janíková, Andrea - Chloupková, Renata - Campr, Vit - Klener, Pavel - Hamouzova, Jitka - Belada, David - Prochazka, Vit - Pytlik, Robert - Pirnos, Jan - Duras, Juraj - Mocikova, Heidi - Bortlíček, Zbyněk - Kopalova, Natasa - Mayer, Jiří - Trneny, Marek
PY  - 2019
TI  - First-line therapy for T cell lymphomas: a retrospective population-based analysis of 906 T cell lymphoma patients
JF  - Annals of hematology
VL  - 98
IS  - 8
SP  - 1961-1972
EP  - 1961-1972
PB  - Springer Verlag
SN  - 09395555
KW  - T cell lymphoma
KW  - Auto-SCT
KW  - Etoposide
KW  - Prognosis
UR  - http://dx.doi.org/10.1007/s00277-019-03694-y
L2  - http://dx.doi.org/10.1007/s00277-019-03694-y
N2  - Peripheral T cell lymphomas (PTLs) have a globally poor prognosis. The CHOP regimen shows insufficient efficacy; first-line consolidation with autologous stem cell transplantation (auto-SCT) is a promising strategy but has never been confirmed by randomized data. We analyzed retrospectively 906 patients diagnosed with PTL between 1999 and 2015. Chemotherapy was given to 862 patients, and 412 of them were <60years. In this subset, we compared induction with CHOP (n=113) vs. CHOEP (n=68) and tested auto-SCT (n=79) vs. no SCT (n=73) in the intent-to-treat analysis. The median age of the whole cohort at diagnosis was 60years (range; 18-91); the median follow-up was 4.3years (range; 0.1-17.8). A shorter overall survival (OS) was associated with the male gender, age >= 60years, stage III/IV, performance status >= 2, bulky tumor >= 10cm, and elevated LDH. CHOEP induction showed a better 5-year PFS (25.0% vs. 32.9%; p.001), and 5-year OS (65.6% vs. 47.6%; p.008) than CHOP. Auto-SCT compared to no SCT brought a 5-year OS of 49.2% vs. 59.5% (p.187). Auto-SCT did not influence the OS in low-risk or low-intermediate risk PTLs. The high-intermediate and high-risk IPIs displayed a worse 5-year OS in auto-SCT arm (17.7% vs.46.2%; p.049); however, 73.9% of the patients never received planned auto-SCT. Our population-based analysis showed the superiority of CHOEP over CHOP in first-line treatment. We confirm the 5-year OS of around 50% in PTLs undergoing auto-SCT. However, the intended auto-SCT could not be given in 73.9% of the high-risk PTLs.
ER  -

JANÍKOVÁ, Andrea, Renata CHLOUPKOVÁ, Vit CAMPR, Pavel KLENER, Jitka HAMOUZOVA, David BELADA, Vit PROCHAZKA, Robert PYTLIK, Jan PIRNOS, Juraj DURAS, Heidi MOCIKOVA, Zbyněk BORTLÍČEK, Natasa KOPALOVA, Jiří MAYER a Marek TRNENY. First-line therapy for T cell lymphomas: a retrospective population-based analysis of 906 T cell lymphoma patients. \textit{Annals of hematology}. New York: Springer Verlag, 2019, roč.~98, č.~8, s.~1961-1972. ISSN~0939-5555. Dostupné z: https://dx.doi.org/10.1007/s00277-019-03694-y.

Podrobný výpis o publikaci